9:09 - 27.11.2016 / Views: 7
Johnson & Johnson approaches Actelion about takeover deal
Johnson & Johnson approaches Actelion about takeover deal

U.S. healthcare company Johnson & Johnson (JNJ.N) said on Friday it was in preliminary talks with Actelion (ATLN.S) about a potential takeover of Europe’s largest biotech firm, currently valued at about $20 billion.

Lung disease specialist Actelion confirmed it had been approached and said there was no certainty a deal would occur.

An acquisition of the Swiss company would boosts J&J’s drug pipeline and diversify its prospects. J&J’s biggest product, the arthritis drug Remicade, faces cheaper competition from Pfizer Inc (PFE.N).

inRead invented by Teads

Actelion shares surged nearly 19 percent to a peak of 187.70 Swiss francs on Friday, valuing the company at around $20 billion. They closed up 16.8 percent at 184.50 Swiss francs, more than matching the stock’s total gains this year up to Thursday’s close.

The company’s focus on rare diseases makes it an attractive takeover target because drugs in that area are less prone to pricing pressure.

Analysts at Bank of America Merrill Lynch and Bryan Garnier said a bid for Actelion could be worth up to 220 Swiss francs ($217) or 250 Swiss francs ($246) per share, respectively, stoked by appetite in the industry for fast-growing businesses.

Actelion’s Opsumit and Uptravi drugs to treat the life-threatening condition of high pressure in blood vessels to the lungs will generate more than $4.6 billion in combined 2020 sales, analysts forecast, up from an estimated $1.4 billion this year.

J&J’s shares finished up nearly 1 percent at $114.13.

J&J’s chief executive, Alex Gorsky, said earlier this year that the company was interested in deals to expand its main consumer, medical device and pharmaceuticals segments. In September, J&J agreed to buy Abbott Laboratories’ (ABT.N) eye care business for about $4.33 billion in cash.

Actelion has long been seen as a takeover target. However, Actelion co-founder and Chief Executive Jean-Paul Clozel, who holds a 3.5 percent stake in the company, has repeatedly said he wants it to remain independent.

In 2011, Clozel rallied shareholders against activist investor Elliott Management’s campaign to put the biotech firm up for sale. Actelion’s shares have more than tripled since then.

There may be broader interest from other suitors in Actelion, according to an investment banker who did not want to be named, who added that a competing bid could come “most likely” from larger Swiss peer Novartis AG (NOVN.S).

Another source close to Novartis, however, said the company was not very impressed by Actelion’s drug pipeline.

A spokesman from Novartis declined to comment.

U.S. lawmakers push for answers on Trump team’s Russia ties
15:15 - 16.02.2017

A crisis over the relationship between President Donald Trump’s aides and Russia deepened on Wednesday as a growing number of Trump’s fellow Republicans demanded expanded congressional inquiries into the matter. Trump sought to focus attention on what he called criminal intelligence leaks about his ousted national security adviser, Michael Flynn. Trump forced Flynn out on

North Korea launches ballistic missile test
12:12 - 13.02.2017

North Korea fired off a ballistic missile into the East Sea from Banghyeon North Pyongan Province early Sunday, according to South Korean officials. South Korea’s military is analyzing exactly what type of missile it was but there’s a strong possibility that it was a midrange Musudan type, according to officials. North Korea has test fired

US investigators corroborate some aspects of the Russia dossier
12:12 - 13.02.2017

For the first time, US investigators say they have corroborated some of the communications detailed in a 35-page dossier compiled by a former British intelligence agent, multiple current and former US law enforcement and intelligence officials tell CNN. As CNN first reported, then-President-elect Donald Trump and President Barack Obama were briefed on the existence of

After day in South Korea court, Samsung chief awaits arrest decision
15:15 - 16.02.2017

Samsung Group leader Jay Y. Lee left a Seoul court after more than eight hours on Thursday to await a decision on whether he will be arrested over his alleged role in a corruption scandal that has engulfed President Park Geun-hye. The 48-year-old Lee, wearing a dark coat and navy tie, kept his head down

Key business lobby warns UK not to play favorites in Brexit
12:12 - 13.02.2017

A key business lobby warned Britain’s government Monday not to play favorites among industries when it negotiates the country’s exit from the European Union, saying that ignoring any sector would hurt the entire economy. The Confederation of British Industries and the international law firm Clifford Chance also said in a new report that it is

Trump, South Korea’s Hwang agree to strengthen defenses against North Korea: White House
16:16 - 30.01.2017

U.S. President Donald Trump and South Korean Acting President Hwang Kyo-ahn agreed to take steps to strengthen joint defense capabilities to defend against North Korea’s nuclear threat, the White House said on Sunday after a telephone call between the two leaders. “President Trump reiterated our ironclad commitment to defend (South Korea), including through the provision

After day in South Korea court, Samsung chief awaits arrest decision
15:15 - 16.02.2017

Samsung Group leader Jay Y. Lee left a Seoul court after more than eight hours on Thursday to await a decision on whether he will be arrested over his alleged role in a corruption scandal that has engulfed President Park Geun-hye. The 48-year-old Lee, wearing a dark coat and navy tie, kept his head down

BT supports Google’s Android in EU antitrust row
21:21 - 06.02.2017

BT (BT.L) has become the first major telecoms company to back Google (GOOGL.O) in a battle with EU regulators, defending the “stability and compatibility” of the Android operating system, which is in the sights of anti-trust regulators. The EU says Google stifles competition by forcing smartphone makers to pre-install its search function and browser to

Nokia beats market expectations, sees network market improving
14:14 - 02.02.2017

Finnish network equipment maker Nokia reported its quarterly profits fell less than expected, helped by cost cuts and the acquisition of Alcatel-Lucent, and said the tough global market was starting to stabilize. Nokia and its rivals, Sweden’s Ericsson and China’s Huawei [HWT.UL], have struggled lately as telecom operators’ demand for faster 4G mobile broadband equipment

U.S. lawmakers push for answers on Trump team’s Russia ties
15:15 - 16.02.2017

A crisis over the relationship between President Donald Trump’s aides and Russia deepened on Wednesday as a growing number of Trump’s fellow Republicans demanded expanded congressional inquiries into the matter. Trump sought to focus attention on what he called criminal intelligence leaks about his ousted national security adviser, Michael Flynn. Trump forced Flynn out on

BT supports Google’s Android in EU antitrust row
21:21 - 06.02.2017

BT (BT.L) has become the first major telecoms company to back Google (GOOGL.O) in a battle with EU regulators, defending the “stability and compatibility” of the Android operating system, which is in the sights of anti-trust regulators. The EU says Google stifles competition by forcing smartphone makers to pre-install its search function and browser to

Iran says it sealed Boeing plane deal at half price
20:20 - 26.12.2016

Iran said on Sunday it had negotiated to pay only about half the announced price for 80 new Boeing (BA.N) airliners in an order that the American planemaker had said was worth $16.6 billion. Boeing and its European rival Airbus (AIR.PA) have both signed huge contracts this month to supply airliners to Iran, the first